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SUMMARY
The OXA -lactamases were among the earliest -lactamases de-
tected; however, these molecular class D -lactamases were orig-
inally relatively rare and always plasmid mediated. They had a
substrate profile limited to the penicillins, but some became able
to confer resistance to cephalosporins. From the 1980s onwards,
isolates of Acinetobacter baumannii that were resistant to the car-
bapenems emerged, manifested by plasmid-encoded -lactama-
ses (OXA-23, OXA-40, and OXA-58) categorized as OXA en-
zymes because of their sequence similarity to earlier OXA
-lactamases. It was soon found that every A. baumannii strain
possessed a chromosomally encodedOXA-lactamase (OXA-51-
like), some of which could confer resistance to carbapenemswhen
the genetic environment around the gene promoted its expres-
sion. Similarly,Acinetobacter species closely related toA. bauman-
nii also possessed their own chromosomally encoded OXA -lac-
tamases; some could be transferred to A. baumannii, and they
formed the basis of transferable carbapenem resistance in this spe-
cies. In some cases, the carbapenem-resistant OXA -lactamases
(OXA-48) have migrated into the Enterobacteriaceae and are be-
coming a significant cause of carbapenem resistance. The emer-
gence of OXA enzymes that can confer resistance to carbapenems,
particularly in A. baumannii, has transformed these -lactamases
from a minor hindrance into a major problem set to demote the
clinical efficacy of the carbapenems.
INTRODUCTION
The simplest classification for -lactamases has been based onmolecular structure (1); in this scheme, there are four major
classes. Classes A to C have been well documented as both chro-
mosomally encoded and plasmid-mediated enzymes (2). The
class D -lactamases have been much more elusive and, for the
most part, were identifiable only as plasmid-encoded -lactama-
ses in Gram-negative bacteria. These early enzymes were essen-
tially penicillinases, which, unlike the class A -lactamases, could
hydrolyze and confer resistance to oxacillin as well as penicillin,
hence the name oxacillinases and the prefix OXA. When the sub-
strate profile of the early OXA enzymes was considered by the
scheme reported by Bush et al., these enzymes were designated
2d (3).
EARLY OXA -LACTAMASES
Hedges et al. (4) demonstrated that plasmid-encoded -lactama-
ses in Gram-negative bacilli could be divided into two groups, the
ubiquitous TEM enzymes and another, small group that was dis-
Address correspondence to Sebastian G. B. Amyes, s.g.b.amyes@ed.ac.uk.
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tinguishable by its ability to hydrolyze oxacillin. Unlike the TEM
enzymes, this grouphad a heterogeneous substrate profile andwas
encoded by amuch narrower range of plasmids. These-lactama-
ses had properties similar to those found on a plasmid (R1818)
identified by Datta and Kontomichalou (5), which was later re-
namedR46 (6). These enzymes had a lower specific activity against
penicillin than the TEM -lactamases. On the other hand, they
had much higher activity against oxacillin and methicillin. Their
emergence presumably coincided with the widespread introduc-
tion of flucloxacillin and methicillin for the treatment of staphy-
lococcal infections. They were also relatively less effective against
first-generation cephalosporins and are poorly inhibited bymajor
class A -lactamase inhibitors such as clavulanic acid.
Closely related -lactamases were originally distinguished by
their isoelectric points. Sykes and Matthew (7) identified three
distinct oxacillinases, named OXA-1, OXA-2, and OXA-3. The
first two possessed a characteristic shared bymost of themembers
of this class, in that they were inhibited by chloride ions (8). The
first gene to be sequenced was from plasmid R46 and was actually
blaOXA-2 (9, 10). The first blaOXA-1 gene to be sequenced was part
of a transposon carried on plasmid RGN238 (11). Compared with
the OXA-2 -lactamase, there was only about 48% homology.
There was, however, a degree of conservation around the active-
site serine at position 71 and a leucine at position 179.
71
|
APDSTFKIALS
SPASTFKIPHT
179
|
SLKISPEEQIQFLRK  OXA-1
SLAISAQEQIAFLRK  OXA-2
These were the first motifs that were identified in the OXA
enzymes, and they have become an important characteristic in the
examination of these enzymes. The location of the blaOXA-1 gene
was in a Tn21-derived transposon, inserted between the aad gene
encoding aminoglycoside resistance and its promoter. Interest-
ingly, the rather dissimilar blaOXA-2 gene was found in exactly the
same position, which suggests some strong evolution pressure not
just for the presence of these genes in the bacterial cell but also for
their carriage within this specific transposon. Subsequent OXA
enzymes have been given a unique number based on the chrono-
logical order in which they were discovered, and later, these num-
bers were verified by their unique amino acid sequence by the
Lahey Clinic (http://www.lahey.org/Studies/), where the com-
plete list of OXA-lactamases can be found. Closely related num-
bers do not reflect similarities but merely the order in which they
were reported.
A new group of plasmid-borne -lactamases was found in Pseu-
domonas aeruginosa (12). They were called PSE (Pseudomonas-
specific enzymes) because they were considered to be specific to
Pseudomonas aeruginosa (13). There were four main enzymes,
PSE-1 to PSE-4. The genes were transferable to Escherichia coli
both in the laboratory (14) and in clinical isolates (13). The des-
ignation of these enzymes as Pseudomonas specific was clearly in-
correct; however, it was only when the genes were sequenced that
it was found that they were not a homogenous group. All enzymes
were active against the anti-Pseudomonas penicillin carbenicillin,
but Philippon et al. (15) noticed that one of them (PSE-2) was also
able to hydrolyze oxacillin. When the genes were sequenced,
PSE-2 was closely related to the OXA -lactamases, but the other
PSE enzymes were not, despite a similar substrate profile. PSE-2
had only about 36% homology to OXA-2 but was much closer in
structure to OXA-5 (16). There was great diversity among the five
enzymes studied by this group, which suggested that these en-
zymes came from distant sources and had evolved from an ances-
tral gene a long time ago. Because of the close structural similarity
of PSE-2 with the OXA -lactamases, it was later proposed that
this enzyme should be reclassified as OXA-10 (17).
OXA EXTENDED-SPECTRUM -LACTAMASES
The role of the class D OXA enzymes was considered to be sec-
ondary to themuchmore ubiquitous class A enzymes, particularly
in conferring resistance to the penicillins. Some of them had been
identified originally in Pseudomonas aeruginosa. In the 1980s, this
organism was responding well to the third-generation cephalo-
sporin ceftazidime. However, a strain of Pseudomonas aeruginosa
was identified,which had been isolated fromapatient inTurkey in
October 1991 (17). The bacteriumwasmultiresistant, particularly
to ceftazidime. This resistance was transferable, and when se-
quenced, the enzyme had 2 amino acid changes from the OXA-10
enzyme, altering an arginine at amino acid 143 to serine and a
glycine at position 157 to aspartate. Although the OXA-10 -lac-
tamase did provide weak hydrolysis of cefotaxime, ceftriaxone,
and aztreonam (18), the mutation considerably increased the
binding of ceftazidime to the active site. The new enzyme, desig-
nated OXA-11, was the first example of an OXA enzyme that had
become, through mutation, an extended-spectrum -lactamase
(ESBL).
Besides OXA-11, there have been several more ESBLs derived
from OXA-10, namely, OXA-13, OXA-14 (19), OXA-16 (20),
OXA-17 (21), OXA-19 (22), and OXA-28 (23). All of these ESBLs
have been found in Pseudomonas aeruginosa. They possess up to
nine variations from the parental enzyme. The effect of these
changes from the parental enzyme on the function of the protein
and, thus, the resistance profile has not been studied. It is inter-
esting to note that the glycine-to-aspartate mutation at position
157 found in OXA-11 is also found in four of these OXA-10 ESBL
derivatives. OXA-14 has this mutation only, indicating that this is
the crucial mutation for high-level ceftazidime resistance (19).
The reason why this mutation affects ceftazidime resistance is not
clear: it certainly affects the kinetics, but the mutation does not
appear to directly influence the active site (24); rather, it affects the
dimerization of the enzyme, and this may have a profound effect
on the hydrolysis of ceftazidime by increasing the bonding of
cephalosporin.
The reason why other OXA-10-derived ESBLs have emerged is
less easy to identify. There are two OXA-10-like ESBLs; both have
the glycine-to-aspartate substitution at position 157, but OXA-11
has the additional asparagine-to-serine mutation at position 143,
and OXA-16 has the alanine-to-threonine mutation at position
127. Neither of these mutations is found in any of the other OXA-
10-like ESBLs, suggesting that they are not the precursors to these
enzymes and also, perhaps, that they are not so important in ceph-
alosporin resistance. OXA-19 has nine mutations compared to
OXA-10, andmany of the laterOXA-10-like ESBLs (OXA-28, -35,
-145, and -147) have most of these mutations, suggesting that this
has been the most successful group. One OXA-10-like ESBL,
OXA-17, has a single asparagine-to-serine mutation at position
73. This is near the active site and confers resistance to cefotaxime
and ceftriaxone but virtually no resistance to ceftazidime (21).
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TheOXA-2-like ESBLs aremuchmore diverse. There are six of
them, and each of them has a single mutation from the parental
-lactamase. In only two of them is the mutation at the same
position: in OXA-15, there is an aspartate-to-glycine substitution
at position 149 (25), and in OXA-36, there is an aspartate-to-
tyrosine mutation at position 149. The dissimilarity between the
substituted amino acids glycine and tyrosine suggests that the loss
of aspartate is the crucial aspect of the hydrolysis of cephalospo-
rins, rather than the acquisition of either of these substituted
amino acids.
Although often crucial to the resistance profile of Pseudomonas
aeruginosa, theOXA-derived ESBLs have hardly been identified in
other species, so they do not appear to be spreading. One enzyme,
OXA-21, was found in a strain of Acinetobacter baumannii, and
this was the first report of an OXA -lactamase sequence in this
species (26). The clinical impact of these enzymes is largely un-
known, as so few epidemiological studies have been performed
(18), but the role of OXA ESBLs does not appear to be very signif-
icant compared with the role of pandemic CTX-M ESBLs (18).
OXA-23-LIKE -LACTAMASES
The first group of carbapenem-resistant OXA-type -lactamases
to be identified in A. baumannii was the OXA-23 group. The
OXA-23 -lactamase was first identified in an A. baumannii iso-
late collected in Edinburgh, United Kingdom, in 1985, interest-
ingly the same year that imipenemwas first approved for use (27).
The isolate was found to haveMICs of imipenem of 16mg liter1,
and the resistance phenotype was transferable, indicating a plas-
mid location (28). The sequence was published in 2000 (29), and
subsequently, as shown in Table 1 and Fig. 1, 18 further alleles of
the blaOXA-23 gene have since been identified. The genes for this
group of enzymes are frequently plasmid-borne and have been
found in many Acinetobacter species as well as species belonging
to the Enterobacteriaceae (Table 1). The discovery of several
blaOXA-23-like genes (blaOXA-23, blaOXA-102, blaOXA-103, blaOXA-105,
blaOXA-133, and blaOXA-134) on the chromosome of Acinetobacter
radioresistens isolates indicates that this species is the likely natural
source of this enzyme group (30–32). Comparison of the GC con-
TABLE 1 Carbapenem-hydrolyzing OXA-type carbapenemasesa
Enzyme group Enzyme(s)
No. of
enzymes
in group Location(s) Host species
OXA-23-like OXA-23, OXA-27, OXA-49, OXA-73, OXA-102, OXA-103,
OXA-105, OXA-133, OXA-134, OXA-146,
OXA-165–OXA-171, OXA-225, OXA-239
19 C and P A. baumannii, A. junii, A. radioresistens,
A. pittii, Proteus mirabilis,
Acinetobacter phenon 5, Acinetobacter
phenon 6/ct 13TU, A. nosocomialis,
Acinetobacter genomic species 10/11,
A. lwoffii, Klebsiella pneumoniae, A.
baylyi
OXA-40-like OXA-40, OXA-25, OXA-26, OXA-72, OXA-139, OXA-160,
OXA-207
7 C and P A. baumannii, A. haemolyticus, A. pittii,
A. baylyi, Pseudomonas aeruginosa, A.
calcoaceticus, K. pneumoniae
OXA-51-like OXA-51, OXA-64–OXA-71, OXA-75–OXA-80, OXA-82–
OXA-84, OXA-86–OXA-95, OXA-98–OXA-100, OXA-
104, OXA-106–OXA-113, OXA-115–OXA-117, OXA-
120–OXA-128, OXA-130–OXA-132, OXA-138, OXA-
144, OXA-148–OXA-150, OXA-172–OXA-180, OXA-
194–OXA-197, OXA-200–OXA-203, OXA-206, OXA-
208, OXA-216, OXA-217, OXA-219, OXA-223, OXA-
241, OXA-242, OXA-248–OXA-250, OXA-254
95 C and P A. baumannii, A. nosocomialis,
Enterobacter cloacae, Escherichia coli,
K. pneumoniae
OXA-58-like OXA-58, OXA-96, OXA-97, OXA-164 4 C and P A. baumannii, A. pittii, A. nosocomialis,
Acinetobacter phenon 6/ct 13TU, A.
junii, Acinetobacter genomic species 9,
A. bereziniae, A. calcoaceticus, A.
radioresistens, E. cloacae, Comamonas
testosteroni, E. coli, K. pneumoniae,
Delftia acidovorans
OXA-134a-like OXA-134a, OXA-186–OXA-191 7 C A. lwoffii
OXA-143-like OXA-143, OXA-182, OXA-231, OXA-253, OXA-255 5 P A. baumannii, A. pittii
OXA-213 OXA-213 17 C A. calcoaceticus
OXA-214-like OXA-214, OXA-215 5 C A. haemolyticus
OXA-211-like OXA-211, OXA-212, OXA-309 6 C A. johnsonii
OXA-229-like OXA-228–OXA-230, OXA-257 8 C A. bereziniae
OXA-235-like OXA-235–OXA-237, OXA-278 7 C A. schindleri
OXA-48-like OXA-48, OXA-48b, OXA-162, OXA-163, OXA-181,
OXA-199, OXA-204, OXA-232, OXA-244, OXA-245,
OXA-247
11 C and P E. cloacae, K. pneumoniae, E. coli,
Shewanella xiamenensis, Citrobacter
freundii, Serratia marcescens,
Providencia rettgeri, Klebsiella oxytoca,
Enterobacter sakazakii, A. baumannii
a See references 30–32, 34, 40, 41, 43, 45, 46, 53, 55, 56, 58–60, 62, 64, 65, 68, 69, 71, 72, 78, 86, 88, 99, 100, 104, 119, 120, 126–128, 133, 157, 161, 162, 165, 166, and 182–201 and
the Lahey Clinic website (http://www.lahey.org/Studies/). C, chromosomal; P, plasmid.
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FIG 1 Maximum likelihood amino acid tree of theOXA-type-lactamases found inAcinetobacter species. For enzymes forwhich a designationwas not available,
the species and strain designation are used instead. Due to its large size, the OXA-51 enzyme group has been collapsed so that the other enzyme groups can be
more easily seen. Relationships between the OXA-51-like enzymes are shown in Fig. 5. The tree was implemented in SeaView version 4.2.5 (172) with PhyML
using a Le andGascuel (LG)model (173). Support was estimated by using approximate likelihood ratio tests, the results of which label the branches. The tree was
visualized by using FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/) and is midpoint rooted.
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tent of a gene with that of the whole genome of an organism
provides evidence for whether that gene originates from that or-
ganism, as the two GC contents are likely to be similar if this is the
case. The blaOXA-23-like genes from Acinetobacter radioresistens
have a GC content of 37.5%, which is lower than the average for
the A. baumannii genome (33), suggesting that they have been
recently acquired by A. baumannii.
Kinetic studies have been performed on three OXA-23-like
enzymes:OXA-23,OXA-27, andOXA-146 (Table 2) (34–36). The
kinetic properties determined vary considerably between studies,
even for the same enzyme, making it difficult to make valid com-
parisons. The enzymes are able to hydrolyze oxyiminocepha-
losporins, aminopenicillins, piperacillin, oxacillin, and aztreonam
in addition to the carbapenems (34, 37). Among the carbapenems,
OXA-23 has a much higher turnover rate for imipenem than for
meropenem, ertapenem, or doripenem (36). Despite the relatively
low turnover rates for carbapenems displayed by these enzymes, it
appears that they counter this through the presence of a “hydro-
phobic bridge” across the top of the active site, formed by phenyl-
alanine 110 and methionine 221 (35), as the presence of a corre-
sponding bridge in OXA-40 has been shown to be responsible for
tight binding of the carbapenems (38, 39). Recently, it was dem-
onstrated that OXA-146 has an expanded hydrolytic spectrum
that includes ceftazidime, which is not hydrolyzed by the other
class D OXA-type carbapenemases, while retaining its activity
against the carbapenems (35). This is the first observation of an
OXA-type carbapenemase with ESBL properties, which may
prove to be problematic in the future. This difference in spectrum
is due to the duplication of an alanine residue at position 220,
within the 5-6 loop of the enzyme. This duplication pushes the
methionine 221 out of a positionwhere it can form the hydropho-
bic bridge, thus removing steric clashes between methionine 221
and ceftazidime and aztreonam.
The production of OXA-23 by an A. baumannii strain is
enough to confer resistance to the carbapenems. As shown in Ta-
ble 3, when a low-copy-number plasmid vector carrying a cloned
blaOXA-23 gene is put into sensitive A. baumannii type strain CIP
70.10, MICs of the carbapenems are increased to 16 g ml1, the
breakpoint for considering strains to be resistant (40). However,
when the blaOXA-23 gene is carried in a strain that also expresses the
AdeABC efflux pump, the MICs are increased to 32 g ml1.
This indicates that, unlike some of the other OXA-type carbapen-
emases, strains do not require other resistance mechanisms to
work in synergy with OXA-23 to be carbapenem resistant, al-
though high levels of resistance are achieved only when there are
other mechanisms present.
OXA-40/24-LIKE -LACTAMASES
The second group of OXA-type -lactamases from A. baumannii
to be identified was the OXA-40 group. The founding member of
this group, OXA-24, which was subsequently renamed OXA-40,
was identified in isolates in 1997, which were part of an outbreak
in Spain (41). A further 6 enzyme variants have since been discov-
ered (Table 1 and Fig. 1). While initially found only in isolates of
A. baumannii, more recent reports have identified blaOXA-40-like
genes on plasmids in other Acinetobacter species as well as in P.
aeruginosa and Klebsiella pneumoniae (Table 1). The GC content
of the blaOXA-40-like genes is 34.1%, which is considerably lower
than the average for the A. baumannii genome, indicating that
TABLE 2 Enzyme kinetic measurements illustrating the ability of the OXA-type -lactamases to hydrolyze carbapenems
Enzyme Group
Imipenem Meropenem
Referencekcat (s
1) Vmax (%) Km (M)
kcat/Km ratio
(s1 mM1) kcat (s
1) Vmax (%) Km (M)
kcat/Km ratio
(s1 mM1)
OXA-23 23 0.35 4.8 73 0.068 1 68,000 36
OXA-23 23 0.49 0.204 0.0024 35
OXA-27 23 0.1a 20 0.04a 15 34
OXA-146 23 0.043 0.046 0.00093 35
OXA-40 40 4a 20 2a 775 41
OXA-40 40 0.1 6.5 15 42
OXA-40 40 1 0.58 0.00172 0.37 0.0099 0.037 43
OXA-40 40 2.1 0.752 0.0028 35
OXA-25 40 3a 11 0.4a 12 34
OXA-26 40 2.4a 3 0.4a 3 34
OXA-51 51 3.1b 11 45
OXA-69 51 0.1 3,600 0.03 0.06 4,500 0.01 46
OXA-58 58 0.1 7.5 13.5 0.01 0.075 0.15 51
OXA-58 58 0.22 1.3 169 49
OXA-134 134 0.1 10 10 0.05 250 0.2 56
OXA-143 143 0.05 5 0.01 0.3 100 0.003 58
OXA-229 229 0.09 30 3 0.01 0.03 0.1 72
OXA-235 235 0.07 0.19 0.00034 0.117 0.016 0.0073 43
OXA-48 48 2 14 145 0.1 200 0.5 62
OXA-48 48 4.8 13 370 0.07 11 6 64
OXA-163 48 0.03 530 0.05 0.07 2,200 0.03 64
OXA-181 48 4 40 100 0.1 70 1 69
OXA-232 48 1 35 30 0.1 125 1 69
a Percent relative to penicillin G.
b Percent relative to ampicillin.
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these genes are very unlikely to have originated from within this
species (Table 4) (33).
The kinetic properties of three members of the OXA-40 group
have been determined: OXA-40, OXA-25, and OXA-26 (Table 2)
(34, 35, 41–43). In general, the enzymes can hydrolyze the peni-
cillins but appear to show weak activity against cephalosporins
and the carbapenems.However, as shown inTable 2, the estimates
of the kinetic parameters vary considerably. Of the three enzymes,
OXA-40 demonstrated the highest activity against the carbapen-
ems. The publication of the crystal structure of OXA-40 in 2007
began to demonstrate the basis for the substrate specificity of the
enzyme (38), and this has been followed more recently by crystal
structures of OXA-40 bound to -lactamase inhibitors and to the
carbapenem doripenem (39, 44). The structure solved by Santil-
lana et al. (38) was the first to identify a hydrophobic bridge
formed by tyrosine 112 and methionine 223 (OXA-40 number-
ing), which restricts access to the active site of the enzyme. This
feature has since been identified in other OXA-type -lactamases
such as OXA-23 (35). By performing site-directed mutagenesis of
tyrosine 112 and methionine 223, the authors of that study pro-
vided evidence that these residues are responsible for orienting the
carbapenems in the active site, with themutated enzymes demon-
strating a reduced ability to hydrolyze imipenem (38, 44).
Isolates that carry an OXA-40-like -lactamase are typically
resistant to the carbapenems. In a study where the blaOXA-40 gene
was insertionally inactivated, the bacterium became more sensi-
tive to the carbapenems, penicillins, and cephalosporins, demon-
strating the role that this enzyme plays in increasing resistance to
the -lactams in general (Table 3) (40). Similarly, insertion of the
cloned blaOXA-40 gene on low-copy-number plasmid pAT801 by
transformation into carbapenem-sensitive clinical strains also in-
creases the MIC to 32 mg liter1 (Table 3) (40). However, as
with blaOXA-23 described above, when blaOXA-40 is inserted into a
sensitive laboratory strain, the MIC is increased only to a moder-
ate 4mg liter1, which increases to 8mg liter1 when inserted into
the same strain that also expresses the AdeABC efflux pump.
These data demonstrate that for OXA-40, as for OXA-23, a range
of resistancemechanisms work in concert to achieve high levels of
carbapenem resistance.
OXA-51-LIKE -LACTAMASES
The largest group of OXA-type-lactamases identified to date are
the OXA-51-like -lactamases. The founding member of the
group, OXA-51, was first identified in A. baumannii isolates from
Argentina isolated in 1996 (45). These enzymes are intrinsic to A.
baumannii and are naturally found on the chromosome of this
species, which has led to the identification of 95 enzyme variants
to date (Table 1). The huge number of variants, alone, is an indi-
cation that these chromosomally encoded enzymes have been un-
der considerable selective pressure from antibiotic use, and these
enzymes are not benign and do play a role in resistance. Only two
of the OXA-51-like enzymes have had their kinetic properties
studied: OXA-51 and OXA-69 (Table 2) (45, 46). While the two
enzymes differed in their affinities for both imipenem and mero-
penem, both enzymes demonstrated only weak hydrolytic activity
toward the carbapenems. Despite this weak activity, experiments
have shown that when enzymes from this group are expressed in
vivo, they can dramatically increase the carbapenem MIC for an
isolate, thus conferring resistance. As shown in Table 3, when
OXA-51-like enzymes were expressed in sensitive A. baumannii
and Acinetobacter nosocomialis strains, the carbapenem MICs
were increased to 32 g ml1, a level of resistance comparable to
that conferred by the acquired OXA-type carbapenemases in sim-
ilar experiments. While further work is required to determine
whether all members of the OXA-51-like group are able to confer
TABLE 3 Carbapenem MICs for wild-type and transformed recipient
strains encoding OXA-type -lactamasesa
Strain
Enzyme
group
MIC (g ml1)
ReferenceImi Mer
A. baumannii CIP 70.10 0.25 0.25 40
A. baumannii BM4547 0.5 0.5 40
A. baumannii ATCC 17978 0.125 0.5 36
A. baumannii CIP 70.10 OXA-23 23 16 16 40
A. baumannii BM4547 OXA-23 23 32 32 40
A. baumannii ATCC 17978
OXA-23
23 16 64 36
A. baumannii CLA-1 OXA-40 2 4 40
A. baumannii 17978 0.25 0.5 43
A. baylyi 0.125 0.25 43
A. baumannii CLA-1 OXA-40 40 32 32 40
A. baumannii 17978 OXA-40 40 32 32 43
A. baumannii CIP 70.10 OXA-40 40 4 4 40
A. baumannii BM4547 OXA-40 40 8 8 40
A. baylyi OXA-40 40 32 32 43
A. nosocomialis ATCC 17903 0.12 0.25 161
A. baumannii ATCC 15151 0.5 159
A. nosocomialis ATCC 17903
OXA-138
51 32 32 161
A. baumannii ATCC 15151
OXA-82
51 32 159
A. baumannii CIP 70.10 OXA-58 58 2 2 40
A. baumannii BM4547 OXA-58 58 32 32 40
A. baumannii CIP 70.10 OXA-97 58 2 2 54
E. coli TOP10 0.06 0.06 56
E. coli TOP10 OXA-134 134 0.5 0.5 56
A. baumannii ATCC 19606 0.19 0.19 58
A. baumannii ATCC 19606
OXA-143
143 32 32 58
E. coli TOP10 0.12 71
E. coli TOP10 OXA-211 211 0.25 71
E. coli TOP10 OXA-213 213 0.25 71
E. coli TOP10 OXA-214 214 0.12 71
E. coli TOP10 0.06 0.03 72
E. coli TOP10 OXA-229 229 0.12 0.06 72
A. baylyi OXA-235 235 1 2 43
A. baumannii 17978 OXA-235 235 3 4 43
K. pneumoniae CIP53153 0.06 0.06 62
E. coli DH10B 0.06 0.06 62
E. coli TOP10 0.12 0.01 64
E. coli HB4 0.25 0.25 69
E. coli J53 0.06 0.03 200
E. coli HB101 0.12 0.03 65
K. pneumoniae CIP53153 OXA-48 48 2 0.25 62
E. coli DH10B OXA-48 48 2 0.25 62
E. coli TOP10 OXA-48 48 0.5 0.1 64
E. coli HB101 OXA-48 48 0.5 0.006–0.12 65
E. coli TOP10 OXA-163 48 0.25 0.02 64
E. coli J53 OXA-163 48 0.5 0.03 200
E. coli TOP10 OXA-181 48 0.5 0.06b 99
E. coli HB4 OXA-181 48 32 32 69
E. coli TOP10 OXA-204 48 0.5 0.06b 100
E. coli TOP10 OXA-232 48 0.25 0.06 69
E. coli HB4 OXA-232 48 24 8 69
E. coli HB101 OXA-245 48 2 0.12 65
E. coli J53 OXA-247 48 0.5 0.03 200
a E. coli strain HB4 lacks the porins OmpF and OmpC. Imi, imipenem; Mer,
meropenem.
b The same value was found for OXA-48 in these studies.
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carbapenem resistance, the enzymes of this group remain a major
concern, as they present the possibility that all A. baumannii iso-
lates may be capable of becoming resistant to the carbapenems.
The crystal structure for an OXA-51-like enzyme has not been
solved, but structural modeling and sequence analysis can be used
to identify structural elements involved in activity toward the car-
bapenems. A recent study that conducted in silico docking of
-lactam substrates into a molecular model of OXA-51 showed
that imipenem had the weakest interaction with the enzyme, with
ceftazidime showing the strongest interaction (47). However,
these data are inconsistent with kinetic data where hydrolysis of
ceftazidime was not detected (45, 46). A further study has demon-
strated that the hydrolysis of oxacillin by OXA-51 is thermody-
namically more favorable than the hydrolysis of imipenem and
that a larger conformational change in the tertiary structure of the
enzyme is detectedwhen bound to imipenem thanwhen bound to
oxacillin (48), which is consistent with previous kinetic data (45,
46). Analyses of molecular models of the OXA-51-like enzymes
indicate that there are likely to be differences between the hydro-
lytic profiles of these enzymes. As shown in Fig. 2, amino acid
changes at positions predicted to be located within the active-site
cleft of the enzyme are predicted to alter the shape of the cleft,
which may impact -lactam binding and hydrolysis. Unlike the
OXA-40, OXA-23, and OXA-58 -lactamases, which either have
been shown or are predicted to have a hydrophobic bridge across
the active-site cleft of the enzyme (35, 38, 39, 49), modeling of the
OXA-51-like enzymes suggests that this feature is absent (Fig. 3).
Sequence analysis of the blaOXA-51-like genes provides evidence
that regions of these genes are preferentially altered under the
selective pressure of antibiotic usage (Fig. 4). Evidence for positive
selection, as indicated by a 	N/	S ratio (the ratio of nonsynony-
mous to synonymous nucleotide polymorphisms) of 1, can be
detected between amino acid positions 64 and 97, which surround
the active-site serine residue at position 81; between amino acid
positions 144 and 160, at the start of the 
-loop; and between
amino acid positions 180 and 200, which are located in regions
TABLE 4 Diversity of blaOXA genes found in Acinetobacter species and the housekeeping genes from two MLST schemes
c
Gene No. of alleles 	 (JC) 	N (JC) 	S (JC) 	N/	S ratio % GC
blaOXA genes
blaOXA-51-like 95 0.01789 0.01062 0.04395 0.241638 39.2
blaOXA-23-like 16
a 0.00663 0.00462 0.01401 0.329764 37.5
blaOXA-40-like 7 0.00242 0.00311 0 34.1
blaOXA-58-like 4 0.00178 0.00229 0 37.4
blaOXA-143-like 5 0.05782 0.02823 0.17205 0.164080 34.4
blaOXA-235-like 7 0.05389 0.02825 0.14726 0.191838 45.8
blaOXA-213-like 11
b 0.09899 0.04043 0.34439 0.117396 36.7
blaOXA-214-like 5 0.00802 0.00282 0.02633 0.107102 41.1
blaOXA-211-like 6 0.04659 0.02752 0.11580 0.237651 45.7
blaOXA-229-like 8 0.01263 0.00788 0.03003 0.262404 38.3
Housekeeping genes from Oxford
MLST scheme
gltA 54 0.03454 0.00409 0.16852 0.024270 41
gyrB 98 0.04628 0.00468 0.23992 0.019507 41.6
gdhB 100 0.05113 0.01387 0.22013 0.063008 36.5
recA 64 0.06156 0.00368 0.38409 0.009581 43.2
cpn60 50 0.03184 0.00582 0.13351 0.043592 37.5
gpi 183 0.08073 0.01152 0.35216 0.032712 41.3
rpoD 72 0.03508 0.00900 0.15189 0.059253 39.4
Mean 0.04874 0.00752 0.23575 0.035989 40.07
Housekeeping genes from Pasteur
MLST scheme
cpn60 56 0.05097 0.00484 0.25524 0.018963 37.6
fusA 58 0.04641 0.01566 0.17275 0.090651 44.7
gltA 55 0.06654 0.01098 0.33502 0.032774 41.1
pyrG 29 0.09052 0.00183 0.56740 0.003225 40.8
recA 58 0.10513 0.00898 0.38394 0.023389 43.3
rplB 36 0.05028 0.00862 0.19302 0.044659 44.2
rpoB 56 0.05566 0.00986 0.23000 0.042870 43.7
Mean 0.06650 0.00868 0.30534 0.036647 42.2
a Nucleotide sequences for blaOXA-102, blaOXA-103, and blaOXA-105 were not available.
b Nucleotide sequences for 6 genes were not available.
c Only the nucleotide sequence for blaOXA-134a was available for this group, so it was excluded from the analyses. (Based on data accessed from two Acinetobacter databases [http:
//pubmlst.org/abaumannii/ and http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html] and the NCBI database [http://www.ncbi.nlm.nih.gov/] on 22 August
2013.) JC, Jukes-Cantor.
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corresponding to those suggested to be important for dimer for-
mation in OXA-13 (50). In addition, there are regions, indicated
by blue arrows in Fig. 4, where a 	N/	S ratio could not be deter-
mined, as the polymorphisms coded for only nonsynonymous
changes, which also indicates that they may be under positive
selection. These include amino acid positions 147 to 167, span-
ning most of the 
-loop, and amino acid positions 214 to 237,
which include residues at positions 217 to 219 corresponding to
active-site residues in OXA-40 (38) and a number of residues that
correspond to those involved in carbapenem specificity in OXA-
40, including position 222, which forms one half of the hydropho-
bic bridge (38). In addition to the 	N/	S ratios, evidence for se-
lection can be demonstrated by looking at the amino acid
phylogeny of the enzymes, as shown in Fig. 5. There are six poly-
morphic amino acid positions that are located in more than one
clade of the phylogeny, suggesting that these sites may be under
selection. Five of these positions are in the regions described above
as likely to be important for enzyme function, such as positions
146 and 167 in the 
-loop, position 194 in the region important
for dimer formation, and positions 222 and 225 in the region
predicted to be involved in carbapenem specificity. The remaining
polymorphic site at position 36 is not known to be involved in
enzyme function according to previous data for other OXA-type
enzymes (38, 50) but is located in a region demonstrating high
	N/	S ratios in Fig. 4 and, as such, warrants further investigation
as to the potential role that residues at this position may play.
Together, these data indicate that different OXA-51-like enzymes
are likely to vary in their spectrum of activity, and further charac-
terization of the different enzyme variants is required to deter-
mine this.
OXA-58-LIKE -LACTAMASES
The first member of the OXA-58 group of enzymes was identified
in France in 2003. It was found in a multidrug-resistant A. bau-
mannii clinical isolate that also demonstrated carbapenem resis-
tance (51). Analysis of the enzyme kinetics of OXA-58 revealed
properties similar to those found in other OXA-type enzymes in
A. baumannii (Table 2), with weak activity against the carbapen-
ems and penicillin and an ability to hydrolyze cefpirome and
cephalothin but not ceftazidime, cefotaxime, or cefepime (51). As
seen with OXA-40, enzyme kinetics for OXA-58 measured by dif-
ferent groups gave different results, withOXA-58 demonstrating a
high rate of catalysis but a low substrate affinity for imipenem in a
study by Verma et al. (49) compared with the data generated by
Poirel et al. (51) (Table 2). Mutation of the lysine residue to an
alanine at position 86 in OXA-58 resulted in an almost complete
loss of function of the enzyme, and it has been shown that car-
bamylation of this lysine is required for enzyme activity (49). Sim-
ilarly to OXA-40 and OXA-23, it is thought that the more closed
and hydrophobic nature of the active-site cleft on OXA-58 is re-
FIG 2 Molecular surface models of the active-site cleft of the OXA-51-like enzymes. Structural models were created by using the online protein homology/
analogy recognition engine (phyre) (http://www.sbg.bio.ic.ac.uk/phyre/), using the crystal structure for OXA-40/24 reported by Santillana et al. (38) as a
backbone. Using local numbering, structures were viewed in Swiss-PdbViewerDeepView version 4 (http://spdbv.vital-it.ch/). (A) View down the active-site cleft
of OXA-66 with the active-site serine 80 (red) and an isoleucine at position 129 (blue); (B) view down the active-site cleft of OXA-83 with the active-site serine
80 (red) and a leucine at position 129 (blue); (C) view down the active-site cleft of OXA-66 (from the opposite orientation to panels A and B) with the active-site
serine 80 (red) and a leucine at position 167 (blue); (D) view down the active-site cleft of OXA-82 with the active-site serine 80 (red) and a valine at position 167
(blue).
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sponsible for its ability to hydrolyze the carbapenems (49). As
shown in Table 3, the insertion by transformation of a cloned
blaOXA-58 gene on a low-copy-number vector into a sensitive A.
baumannii strain increased resistance but not to levels considered
resistant (40). However, transformation into a reference A. bau-
mannii strain with increased expression levels of the AdeABC ef-
flux system produced a resistant isolate, demonstrating that clin-
ically significant levels of resistance with this enzyme require
multiple resistance mechanisms to work in concert. Due to the
many resistance mechanisms possessed by A. baumannii, isolates
of this species carrying blaOXA-58-like genes are frequently identified
with high levels of carbapenem resistance (52).
Despite it being 10 years since the first discovery of OXA-58,
only a further three variants of the enzyme have been identified.
An A. baumannii isolate from Singapore isolated in 1996 was
found to encode OXA-96 (53), OXA-97 was encoded by A. bau-
mannii isolates collected between 2001 and 2005 in Tunisia (54),
andOXA-164was identified in isolates recovered fromapatient in
Germany (55). The reasons for this are unclear, although itmay be
due in part to a lack of sequence data. The GC content of the
blaOXA-58-like genes falls below that of the A. baumannii core ge-
nome (Table 4) (33), indicating their likely import from another
bacterial species into A. baumannii, as seen with the blaOXA-23-like
genes (30). Should this import have been a recent event, this may
also explain the lack of diversity observed in this enzyme group.
OXA-134a -LACTAMASE
Following the identification of A. radioresistens as the natural host
of the OXA-23-like enzymes, and as A. baumannii is the natural
FIG 3 Molecular surface models of the active-site cleft of OXA-66 (A) and
OXA-40 (B), showing the absence of a hydrophobic bridge in OXA-66. Using
local numbering, the active-site serine 80 is shown in red. (A) Leucine 110 is in
yellow, phenylalanine 111 is in blue, and tryptophan 222 is in pink; (B)
tyrosine 112 is in blue, and methionine 223 is in pink.
FIG 4 Regions of the OXA-51-like enzymes with evidence of selection. 	N/	S, ratio of nonsynonymous to synonymous polymorphisms, with a ratio of 1
providing evidence for positive selection. Ratios were calculated with DNAsp version 5 (174) in sliding windows 50 nucleotides long, with a step size of 10
nucleotides. The horizontal gray line indicates a 	N/	S ratio of 1; red boxes indicate predicted active-site elements (38); blue boxes indicate predicted sites
involved in specificity for the carbapenems (38); orange boxes indicate predicted sites involved in dimer formation (50); blue arrows indicate regions where a
	N/	S ratio could not be determined, as these regions contained only nonsynonymous polymorphisms; purple boxes indicate -helices; green boxes indicate
-sheets; the red arrow indicates the active-site serine; orange stars indicate the location of residues forming the hydrophobic bridge in OXA-40 (38); and the
bracket indicates the location of the
-loop.
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host for the OXA-51-like enzymes, further studies have been con-
ducted to identify naturally occurringOXA-type enzymes belong-
ing to otherAcinetobacter species. One such study identifiedOXA-
134a from an Acinetobacter lwoffii isolate (56). Screening of
further A. lwoffii isolates has revealed a further six enzyme vari-
ants, OXA-186 to OXA-191, and has shown that the genes for this
group of enzymes are universal in this species (56, 57). The rela-
tionships between the amino acid sequences of theOXA-134a-like
enzymes are shown in Fig. 1.
In A. lwoffii, the blaOXA-134a-like genes do not appear to be very
highly expressed, as the isolates are not resistant to any -lactam
antibiotics. However, when the genes coding for OXA-134a and
OXA-187 were cloned into E. coli, they conferred reduced suscep-
tibility to the carbapenems (Table 3) andmost cephalosporins and
conferred resistance to the penicillins and penicillin–-lactamase
inhibitor combinations (56). The enzyme kinetic measurements
for OXA-134a demonstrated it to be a relatively weak hydrolyzer
of the carbapenems (Table 2). To date, enzymes from this group
have been found only in A. lwoffii and are not presenting as a
clinical problem. However, they represent a reservoir of enzyme
variants that may have the potential to evolve to confer higher
levels of-lactam resistance and be transferred to other species, as
has happened with the OXA-23-like enzymes.
OXA-143 -LACTAMASE
In 2004, three A. baumannii isolates that were resistant to almost
all-lactamantibiotics, including the carbapenems, butwere neg-
ative by PCR for known acquired carbapenem-hydrolyzing -lac-
tamases were identified in patients from Brazil. Further investiga-
tion identified a new enzyme, namedOXA-143 (58). Aswith other
acquired OXA-type -lactamases in A. baumannii, the enzyme
kinetics for OXA-143 showed low levels of carbapenemhydrolysis
(Table 2), but the enzyme conferred high levels of resistance to the
carbapenems when the gene coding for it was transformed into a
previously sensitive A. baumannii reference strain (Table 3) (58).
Analysis of the nucleotide sequences of the blaOXA-143-like genes
indicates that they are under a greater degree of positive selection
than the multilocus sequence typing (MLST) housekeeping genes
of A. baumannii, as would be expected if these genes are under
antibiotic selection (Table 4). Together, these data indicate that, as
with the other acquired OXA-type carbapenemases, this group of
enzymes is capable of conferring high levels of carbapenem resis-
tance when expressed in isolates alongside other resistance mech-
anisms and are likely contributing to carbapenem resistance in
clinical isolates.
To date, this group of enzymes has been identified only in A.
baumannii and Acinetobacter pittii isolates from Brazil and South
Korea and only on plasmids (58–61). The GC content of the en-
zymes is much lower than that for the A. baumannii genome as a
whole (Table 4), which, along with their exclusive plasmidic loca-
tion, strongly suggests that these enzymes originated fromanother
bacterial species. As shown in Fig. 1, the amino acid sequences of
these enzymes are similar to those of other Acinetobacter-derived
OXA-type -lactamases, indicating that another Acinetobacter
species is the original host organism. Note that in Fig. 1, the OXA-
143-like enzymes are very closely related to the OXA-40-like en-
zymes, and itmay even be the case that theOXA-143-like enzymes
are the progenitors of the OXA-40-like enzymes. As larger num-
bers of sequences of both of these enzyme groups become avail-
able, the relationship between these two enzyme groups will be
clarified.
OXA-48 -LACTAMASE
The other carbapenem-hydrolyzingOXA-type enzymes discussed
in this article are largely restricted to Acinetobacter species, in par-
ticular A. baumannii. However, in 2001, a Klebsiella pneumoniae
isolate was obtained from a patient in Istanbul, Turkey, which was
found to be multidrug resistant, including resistance to the car-
bapenems. In this isolate, a new OXA-type -lactamase was iden-
tified and named OXA-48 (62). This enzyme and its variants are
now widespread in K. pneumoniae and other Enterobacteriaceae
and have nowbeen reported inA. baumannii aswell (63), and they
represent one of the most concerning developments in carbap-
enem resistance in the last decade.
Analysis of the enzyme kinetics of OXA-48 showed that the
enzyme has a low level of hydrolytic activity against the carbapen-
ems, with much greater activity against imipenem than against
meropenem (Table 2) (62). In addition, when the enzyme was
cloned into sensitive E. coli reference strains, it resulted in only
modest increases in MICs of the carbapenems (Table 3) (62, 64,
65). Since 2001, 10more namedOXA-48 variants have been iden-
tified (Table 1), although it should be noted that a number of
related unnamed enzymes have been identified in Shewanella spe-
cies, thought to be the original host genus for this group of en-
zymes (66–68). Four of these enzymes, OXA-162, OXA-163,
OXA-181, and OXA-232, have had their kinetic properties mea-
sured, and while OXA-163 appears to be a very poor hydrolyzer of
the carbapenems, OXA-181 and OXA-232 appear broadly similar
to OXA-48 in their activity, with OXA-232 perhaps demonstrat-
ing better hydrolysis of the penicillins, although cross-study com-
parisons may not be very reliable (Table 2) (64, 69). Interestingly,
the lack of activity against the carbapenems in OXA-163 is associ-
ated with an ability to hydrolyze ceftazidime and aztreonam,
which is not detectable in OXA-48, and an increased ability to
hydrolyze cefotaxime and cefepime over OXA-48, making this
enzymemore similar to an ESBL than to a carbapenem-hydrolyz-
ing oxacillinase (64). As with OXA-48, the carbapenemMICs ob-
tained when seven of the variants were cloned into sensitive E. coli
strains showed onlymoderate increases (Table 3). However, when
two of these variants, OXA-181 and OXA-232, were cloned into
sensitive E. coli strains that also lacked the porins OmpF and
OmpC, carbapenem MICs were significantly increased, demon-
FIG 5 Maximum likelihood nucleotide tree of the blaOXA-51-like genes intrinsic toA. baumannii. For enzymes for which a designationwas not available, the strain
designation or gene accession number (http://www.ncbi.nlm.nih.gov/) is used instead. The tree was implemented in SeaView version 4.2.5 (172) with PhyML
using a general time-reversible (GTR)model (173). Supportwas estimated by using approximate likelihood ratio tests, the results ofwhich label the branches. The
treewas visualized by using FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/) and ismidpoint rooted. The gene coding for the enzyme representative of global clone
1 isolates, OXA-66, is highlighted in red; the gene for OXA-69, representative of global clone 2 isolates, is highlighted in blue; and the gene for OXA-71,
representative of global clone 3 isolates, is highlighted in pink. Colored arrows represent genes or branches containing polymorphisms that are observed inmore
than one position within the tree. The arrows are color coded by the amino acid position in the enzyme that the location of the polymorphism codes for and are
labeled with the amino acid change from the consensus that results from the polymorphism. , except for OXA-223 and OXA-242; , except for OXA-242.
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strating that the presence ofOXA-48-like enzymes alongside other
resistance mechanisms can confer high levels of carbapenem re-
sistance (69).
The crystal structure of OXA-48 has been solved and demon-
strates that the enzyme has a differentmechanism for carbapenem
hydrolysis compared to that of the other carbapenem-hydrolyzing
oxacillinases (70).UnlikeOXA-40 andOXA-23,OXA-48 does not
possess a hydrophobic bridge across the active site, demonstrating
that other features must be responsible for the ability to hydrolyze
carbapenems. The tertiary structure of OXA-48 is more similar to
that of OXA-10 andOXA-13 than it is to that of OXA-40 or OXA-
23, and comparisons of the sequences and structures of OXA-48
and OXA-13 indicate that small changes to the amino acid resi-
dues both within the active-site region and in the 5-6 loop of
OXA-48 are likely to be responsible for the enzyme’s ability to
hydrolyze the carbapenems, with the 5-6 loop providing a hy-
drophilic environment harboring water molecules that are re-
quired for hydrolysis (70). In addition, the active-site cleft of
OXA-48 contains a larger hydrophobic region than that in OXA-
13, which allows the hydroxyethyl group of meropenem greater
mobility. This ensures that the antibiotic can be brought into
proximity with a water molecule for deacylation of the antibiotic
(70). These features demonstrate that OXA-48 has followed a dif-
ferent evolutionary trajectory from the OXA-type carbapen-
emases common in Acinetobacter species to develop the ability to
hydrolyze the carbapenems.
OTHER CARBAPENEM-HYDROLYZING OXA-TYPE
-LACTAMASES
Recent studies aiming to identify the naturally occurring OXA-type
enzymes of otherAcinetobacter species have successfully identified
a number of new enzyme groups. These new groups include the
OXA-211-like enzymes from Acinetobacter johnsonii, the OXA-
213-like enzymes from Acinetobacter calcoaceticus, the OXA-214-
like enzymes from Acinetobacter haemolyticus, the OXA-229-like
enzymes fromAcinetobacter bereziniae, and the OXA-235-like en-
zymes from Acinetobacter schindleri (Table 1 and Fig. 1).
The parent enzymes from each of these five groups have been
cloned into sensitive type strains to examine their contribution
toward -lactam resistance, including carbapenem resistance. In
all five cases, the enzymes increased theMICs of the penicillins for
the strains to high levels, had little or no effect on cephalosporin
MICs, and slightly increased carbapenemMICs (Table 3) (43, 71,
72). Two of the enzymes, OXA-229 and OXA-235, have had their
kinetic properties measured and in both cases hydrolyze carbap-
enems at low levels, below those of the acquired carbapenemases
OXA-40 and OXA-58 (43, 72). In addition, the specific activities
of OXA-211, OXA-213, and OXA-214 for the carbapenems have
been measured, and all three enzymes demonstrated better activ-
ity against imipenem than OXA-51 although not as much as
OXA-23 (71). Analyses of the nucleotide sequences of the genes
for the enzymes from these five groups demonstrate that they are
under similar levels of positive selection as the other acquired
carbapenem-hydrolyzing oxacillinases (Table 4). This suggests
that these enzymes are likely to have been evolving under antibi-
otic selective pressure. Together, these data indicate that the en-
zymes from these five groups are able to hydrolyze the carbapen-
ems and represent a reservoir of enzyme variants that could, under
carbapenem selective pressure, evolve to confer clinically signifi-
cant levels of carbapenem resistance and be transferred to other
members of the Acinetobacter genus.
GENETIC LOCATION, MOBILIZATION, AND CONTROL
ISAba1
Insertion sequence (IS) elements play a major role in the mobili-
zation and expression of OXA-type -lactamases. This is particu-
larly evident with the OXAs found in Acinetobacter species, where
insertion sequences are frequently identified in association with
an OXA -lactamase gene (Fig. 6). The most prevalent of these
insertion sequences is ISAba1. The first description of ISAba1was
from A. baumannii isolates in 2001 (73), although sequences cor-
responding to this element had been identified previously (74).
The IS element was located upstream of the blaADC genes, and it
has been shown that in this location, the IS element drives blaADC
gene expression, which confers resistance to cephalosporin anti-
biotics (75). The transposase gene in ISAba1 is formed from two
overlapping open reading frames and requires a frameshift during
translation to forma complete transcript coding for the functional
transposase (76). The transposition frequency of ISAba1 in E. coli
has been reported to be (2.1  0.7)  107 transconjugants per
recipient, or (1.8  5.0)  104 transconjugants per recipient
when a frameshift mutation was introduced, suggesting that con-
ditions under which frameshifts during transcription are likely to
occur are likely to greatly increase the transposition frequency
(76). This is supported by a study that demonstrated ISAba1 mo-
bilization in response to the presence of the frameshift mutagen
acriflavine (77). ISAba1 has since been identified in association
with genes for a number of OXA-type beta-lactamases, such as the
blaOXA-23-like genes, blaOXA-51-like genes, blaOXA-58-like genes, and
blaOXA-235-like genes (Fig. 6) (43, 78, 79). When ISAba1 is located
upstream of blaOXA genes, it tends to increase their expression to a
level that confers resistance to the carbapenems. The location of
ISAba1 25 bp upstreamof blaOXA-23 provides a promoter sequence
that drives transcription of the gene (80, 81). Similarly, when
ISAba1 is located 7 bp upstream of the blaOXA-51-like genes, it pro-
vides a promoter that can increase blaOXA-51-like gene expression
levels by 50-fold (82). This increase in expression levels raised the
MICs of the carbapenems for the isolate and appears to have been
selected by the use of carbapenems to treat the patient fromwhom
the isolates were recovered (82). TheMICs of the carbapenems for
A. baumannii isolates overexpressing blaOXA-51-like genes due to an
ISAba1 insertion have been shown to be the same as those for
isolates expressing acquired OXA-type carbapenemases (83), in-
dicating that all A. baumannii isolates could become carbapenem
resistant through insertion of this promiscuous IS element.
In addition to its role in expression of blaOXA genes, ISAba1 also
appears to be responsible for their mobilization, and a number of
different transposons containing ISAba1 either singly or in multi-
ple copies have been identified (Fig. 6). An example of these trans-
posons is Tn2006, where two oppositely oriented copies of ISAba1
bracket a blaOXA-23 gene. A 9-bp target site duplication is found
before the right inverted repeat of the upstream IS element and
after the right inverted repeat of the downstream IS element,
which indicates that the whole structure is mobilized as one unit
(81). The identification of ISAba1 within a number of different
transposons carrying blaOXA genes, in addition to other antibiotic
resistance determinants, as well as its widespread nature in a num-
ber of Acinetobacter species (84) indicate the important role that
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FIG 6 Mobile genetic elements associatedwith blaOXA genes. Commonly occurring features are color coded. (A and B) See reference 81; (C) see reference 94; (D)
see reference 149; (E) see reference 175; (F) see reference 101; (G) see reference 159; (H) see reference 93; (I) see reference 176; (J) ISAba1 upstream of the
blaOXA-51-like gene (78) and on one occasion found downstream as well (dashed box), see reference 204; (K) see reference 177; (L) see reference 178; (M) see
reference 95; (N) see reference 179; (O) see reference 95; (P) see reference 79; (Q) see reference 90; (R) see reference 149; (S) see reference 79; (T) see reference
92; (U) see reference 79; (V) see reference 89; (W) see reference 180; (X and Y) see reference 79; (Z) see reference 91; (AA) see reference 96; (AB) see reference 64;
(AC) see reference 99; (AD) see reference 97; (AE) see reference 98; (AF) see reference 64; (AG) see reference 100; (AH) see reference 69; (AI) see reference 43;
(AJ) see reference 181; (AK) see reference 25; (AL) see reference 22.
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this IS element plays in genomic plasticity within the acinetobac-
ters.
ISAba3
The insertion sequence ISAba3 is very commonly found in asso-
ciationwith blaOXA-58-like genes, oftenwith one copy upstreamand
one copy downstream of the -lactamase gene, forming a com-
posite transposon (85–88). The element, which contains a single
open reading frame coding for its transposase, was first identified
in an A. baumannii isolate in 2003 (51). When located upstream
and in the opposite orientation to a blaOXA gene, the element
provides a promoter that drives blaOXA gene expression, in aman-
ner similar to that of ISAba1. The lack of target site duplications
either upstream or downstream of the ISAba3 elements suggests
that this insertion sequence may be involved in disseminating
blaOXA genes through a process of homologous recombination
rather than through transposition (79). Inmany cases, the ISAba3
element found upstream of blaOXA-58-like genes is interrupted by
another insertion sequence, such as ISAba2 (79), IS1008 (89), IS18
(79), and ISAba825 (90) (Fig. 6). In these instances, these chimeric
elements often contain hybrid promoters that drive the expression
of the-lactamase gene. For example, the ISAba2/ISAba3 element
contains the35 region of the promoter within the right inverted
repeat of ISAba2, while the 10 region is located within ISAba3.
These chimeric promoters vary in the levels of expression of the
blaOXA-58-like gene that they drive, suggesting that the use of the
carbapenems is selecting for these more complicated genetic
structures (89, 90).
Other Insertion Sequences in Acinetobacter
While ISAba1 and ISAba3 elements are commonly found in asso-
ciation with blaOXA genes in Acinetobacter species, there are many
other IS elements that have been identified less frequently (Fig. 6).
The insertion sequence ISAba125 has been identified in associa-
tion with blaOXA-58 and appears to have been responsible for the
duplication of this genewithin anA. pittii isolate (91). This kind of
gene duplicationmediated by insertion sequences appears to alter
the carbapenem MIC for an isolate. A study of three isolates ob-
tained in Rome that contained one, two, or three copies of
blaOXA-58 found that these isolates had imipenemMICs of 16, 32,
and 128 mg liter1, respectively (92). The duplication of the
blaOXA-58 genes appears to have been mediated by IS26 elements
that bracketed the ISAba2/ISAba3-blaOXA-58-ISAba3 unit. The in-
sertion sequence ISAba4 has been found 25 bp upstream of
blaOXA-23, where it provides a promoter, along with a fragment
corresponding to the right inverted repeat of ISAba4 downstream
of the same blaOXA-23 gene. It has been proposed that this structure
mobilizes the blaOXA-23 gene through one-ended transposition,
and this structure has been named Tn2007 (81). The insertion
sequences ISAba9 and ISAba10 have both been found to be in-
serted into the middle of ISAba1 elements upstream of blaOXA
genes. The chimeric ISAba9/ISAba1 element was located up-
stream of blaOXA-51, where the hybrid promoter increased the ex-
pression level of the blaOXA-51 gene by 8-fold over the level ob-
tained with ISAba1 alone (93). Similarly, the chimeric ISAba10/
ISAba1 element was found upstream of blaOXA-23, where the
hybrid promoter increased the expression level of the blaOXA-23
gene by between 2- and 5-fold and increased carbapenemMICs by
2- to 8-fold compared to the levels with ISAba1 alone (94). In
addition to providing promoters to increase the expression of
blaOXA genes, some insertion sequences have been found to insert
into the middle of blaOXA genes, disrupting their function. The
insertion sequences ISAba15 and ISAba19 have been identified to
be inserted into blaOXA-66 and blaOXA-78, respectively (95). To date,
this has been detected very rarely, suggesting that in most in-
stances, it is more beneficial for the bacteria to carry a gene coding
for a functional OXA-51-like enzyme.
Insertion Sequences Associated with blaOXA-48-like Genes
When the blaOXA-48 gene was first identified, it was found in asso-
ciation with an upstream IS1999 element (62). It was later dem-
onstrated that there is a second IS1999 element downstreamof the
blaOXA-48 gene, and this composite transposonwas namedTn1999
(96). This transposon was shown to be able to mobilize the
blaOXA-48 gene in E. coli although at a low frequency of1 10
7
transconjugants per recipient. Further variants of Tn1999 have
been identified, which contain an IS1R element inserted into the
upstream IS1999 element (named Tn1999.2) (97) or an IS1R ele-
ment inserted into the upstream IS1999 element and a second
IS1R element inserted downstream of blaOXA-48 (named
Tn1999.3) (Fig. 6) (98). As is seen with the chimeric elements in
Acinetobacter species, the chimeric IS1R/IS1999 element contains
a hybrid promoter, and when cloned into a sensitive E. coli strain,
it resulted in a 2-fold-higher rate of hydrolysis of imipenem than
that with just IS1999 alone (97). In this strain, this change was not
significant, but it could improve survival in a strain that also re-
stricts the influx of carbapenems.
Other blaOXA-48-like genes have been found on plasmids in associ-
ation with other insertion sequences (Fig. 6). The blaOXA-163 gene is
located downstream of an ISEcl4 element, a variant of IS4321 (64).
However, unlike the Tn1999 family of transposons, the ISEcl4 ele-
ment does not provide a promoter for blaOXA-163 gene expression;
rather, transcription is driven by the original chromosomal pro-
moter.TheblaOXA-181,blaOXA-204, andblaOXA-232 genes are associated
with ISEcp1 elements but each in slightly different arrangements (69,
99, 100). The blaOXA-181 gene is located downstream of a complete
ISEcp1 element that forms a transposon named Tn2013, which mo-
bilizes the gene through a one-ended transpositionmechanism (99).
TheblaOXA-204 gene is locatedona similar transposon, calledTn2016,
that differs from Tn2013 by an ISkpn15 element inserted into the
upstream ISEcp1 sequence (100). In the case of Tn2016, the ISkpn15/
ISEcp1 chimeric elementdoesnot containahybridpromoter, and the
expression of the gene is likely to be derived from the promoter lo-
cated within ISEcp1. In the case of blaOXA-232, much of the upstream
ISEcp1 element has been lost, along with the upstream target site
duplication, although the 3= fragment of ISEcp1 that remains con-
tains the intact promoter that drives the expression of the blaOXA-232
gene (69). It has been speculated that this deletion of much of the
ISEcp1 element has stabilized the blaOXA-232 gene on the plasmid, as it
can no longer bemobilized by an ISEcp1 transposase (69). The three
completely separate groups of insertion sequences with which
blaOXA-48-like genes are associated may indicate that blaOXA-48-like
genes have beenmobilized from their original location inShewanella
species on several occasions.
XerC/XerD
Unlike the other OXA-type -lactamases found in Acinetobacter
species, the blaOXA-40-like genes are rarely found in associationwith
insertion sequences, with only one report of an associationwith an
upstream IS4 family element (101). Analysis of the nucleotide
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sequence surrounding a plasmid-located blaOXA-40 gene identified
the presence of two conserved inverted repeats on either side of
the gene, separated from one another by a 6-bp variable region
(102). These sequences are homologous to the target sites forXerC
and XerD recombinases, which are usually involved in converting
chromosome and plasmid dimers into monomers (103). It is
likely that the blaOXA-40-like genes are mobilized through a process
of site-directed recombination mediated by XerC and XerD, and
blaOXA-40-like genes flanked by XerC/XerD target sites have been
identified in a number of different plasmid backgrounds (101,
104, 105). In addition, an 11-kb plasmid carrying two copies of
blaOXA-72, belonging to the blaOXA-40-like group, has been found in
a number of isolates fromLithuania (106), with a likely role for the
XerC/XerD recombinases in duplicating the gene.
ISCRs
ISCRs (CR stands for common region) are an unusual type of
insertion sequence, often found in class 1 integrons, that lack in-
verted repeats and transpose through rolling-circle replication
(107). Some of the ESBL OXA-type enzymes have been found in
association with ISCR elements (108–112). While ISCR elements
contain promoters that can be used for downstream gene expres-
sion, this does not appear to be a common role that they play in
relation to the ESBL blaOXA genes. The blaOXA-18 gene appears to
have been mobilized by two ISCR19 elements to insert into an
aac(6=)-Ib, where the promoter in the 5= conserved sequence can
be used for blaOXA-18 expression (108). Similarly, blaOXA-45 is
bracketed by two ISCR5 elements but utilizes a promoter located
in a fragment of an IS1247 element located just upstream (109).
ISCR elements in association with ESBL OXA-type -lactamases
have not been reported very frequently, and this may be due to a
combination of these enzymes not being so frequently identified
and researches overlooking the presence of ISCR elements when
they do identify an OXA-type ESBL.
Plasmids
Most of the groups of OXA-type -lactamases have been identi-
fied on plasmids, with the exception of the more recently identi-
fied groups of OXAs intrinsic to someAcinetobacter species (Table
1). In A. baumannii, these plasmids are many and varied in size
and genetic content but can be broadly grouped based upon their
replicase gene sequences (113). Table 5 summarizes the data from
all studies to date that have analyzed blaOXA gene content and
identified plasmids based upon this typing scheme. While there
are a number of different plasmid groups on which genes for the
acquired OXA-type -lactamases of the OXA-23-like, OXA-40-
like, and OXA-58-like groups can be located, their genes are al-
most always found in associationwith a group 6 plasmid, either by
being carried directly on it or by being located in an isolate that
also carries a group 6 plasmid (114). It has been suggested that the
plasmids belonging to group 6 are self-transmissible and that they
may represent a system for general plasmidmobilization and con-
jugation in A. baumannii (113, 114).
In contrast to the widespread nature of theAcinetobacter blaOXA
genes onmany different plasmids, the blaOXA-48 gene appears to be
located on a single plasmid type (115). The plasmid, which is of
the IncL/M type, has a broad host range among the Enterobacteri-
aceae and was shown to transfer between species at quite a high
frequency of 3.3 105 transconjugants per recipient. This plas-
mid carrying blaOXA-48 has been identified in several species and
has been circulating for at least a decade, indicating that the spread
of this plasmid is largely responsible for the spread of the blaOXA-48
gene (115, 116).
EPIDEMIOLOGY AND CLONALITY
Geographical Dissemination
Resistance to the carbapenems has increased globally in the last
decade, and this is caused in part by the spread ofOXA-type-lac-
tamases. Data from the United States show that the percentage of
A. baumannii isolates resistant to imipenemhas increased from an
average of 10% between 1999 and 2005 to 48% in 2008, and
meropenem resistance has increased from 19% to 57.4% over
the same time period (117). Similarly, a study analyzing 274 A.
baumannii isolates obtained between May 2008 and June 2009
from 16 countries, 14 of which were European countries, found
that 47.1% and 45.2% of isolates were resistant to imipenem and
meropenem, respectively (118). While the general trend is for an
increase in the percentage of resistant isolates, the different blaOXA
genes that are partly responsible for this are not uniformly dissem-
inated globally.
The first blaOXA-23 genewas identified in Europe (37).However,
the second and third genes within this group were identified in
Singapore (34) and China (NCBI accession number AY288523)
(unpublished data), giving an early indication that this group of
-lactamases was widespread. Subsequent studies have identified
isolates carrying blaOXA-23-like genes from all over the world (40,
119–123). Of all of the acquired OXA-type -lactamases, those of
the blaOXA-23-like group currently appear to be the most wide-
spread and are particularly prevalent in Africa (123), South Amer-
ica (120, 124, 125), and East and Southeast Asia (53, 126). While
not as prevalent as the blaOXA-23-like genes, the blaOXA-58-like genes
are also globally distributed (53, 126–129). However, they are de-
tected at very high frequencies in southern European Mediterra-
nean countries such as Italy (130), Greece (131), and Turkey
(132). Until recently, the blaOXA-40-like genes appeared to be re-
stricted largely to the Iberian Peninsula, where they have been the
predominant acquired OXA-type -lactamase (133–135). How-
ever, reports have identified blaOXA-40-like genes in more distant
locations, such as the United States (136) and Asia (31), and in
particular, there are increasingly reports of these enzymes being
identified on plasmids in Taiwan (137, 138). It may be that amore
recent transfer onto plasmids by this enzyme group has limited its
spread to date. In contrast, the blaOXA-143-like enzymes, which are
closely related to the blaOXA-40-like enzymes, have been identified
only in Brazil (58, 61, 125). However, this apparent discrepancy
may be explained by the close cultural connections between South
America, Portugal, and Spain. The first blaOXA-48 gene was de-
TABLE 5 OXA-type -lactamases and plasmid groupsa carried by A.
baumannii isolates.
–Lactamase
Plasmid rep gene
group(s) Reference(s)
OXA-23 1, 6 113, 114, 165, 202
OXA-40 2, 6, 12 105, 106, 113, 114
OXA-72 2 203
OXA-58 1, 2, 3, 4, 6, 8, 10, 12, 14 113, 114, 203
OXA-235 2, 6 43
a As defined by Bertini et al. (113).
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tected in an isolate from Turkey (62), and blaOXA-48-like genes ap-
pear to have spread within Turkey (139), India (140), and some
NorthAfrican countries (141, 142) but have also been identified in
European countries and Russia (see reference 143 for a compre-
hensive list). Until very recently, the blaOXA-48-like genes seemed
not to have spread to America or Southeast Asia. However, the
first reports of blaOXA-48 genes in the United States (144) and Ja-
pan (145) were published in 2013, and it seems likely that this
group of enzymes will successfully spread globally in the near fu-
ture.
Association of blaOXA Genes with Global Lineages
With the rapid improvements toDNA sequencing technology and
the associated decreasing cost, it is becoming more feasible to
study epidemiology throughwhole-genome sequencing and com-
parative genomics. While this approach has not yet become stan-
dard practice due to the cost still remaining relatively high com-
pared to the costs of other typing methods, a few studies have
taken a comparative genomics approach, which has shed light
upon the different antibiotic resistance phenotypes of the bacteria
by identifying blaOXA genes and the supporting genetic elements
that they carry (84, 146–149). The largest of these studies, analyz-
ing 136 Acinetobacter genomes, identified the presence of blaOXA
genes and ISAba1 in a number of different Acinetobacter species
and spread across a number of different evolutionary lineageswith
A. baumannii (84). As more genome sequences become available,
more in-depth analyses associating specific resistance genes with
different genetic backgrounds will be possible.
The more common methods currently used for analyzing the
underlying genetic differences among isolates are multilocus se-
quence typing (MLST) and multilocus sequences analysis
(MLSA). Typically, these methods involve sequencing of frag-
ments of seven housekeeping genes from each isolate and then
either assigning the identified alleles a number, resulting in each
isolate receiving a seven-number code known as its sequence type
(ST), as is the case with MLST, or performing direct analyses on
the nucleotide sequences obtained from the seven genes, as is the
case with MLSA. These approaches are useful as they identify the
underlying genetic relatedness between isolates and can be used to
compare isolates obtained from any location and at any time
point. Two MLST schemes exist for A. baumannii, the Oxford
scheme (150) and the Pasteur scheme (151). It shouldbenoted that
thegpigene included in theOxfordscheme isnotalwayspresent (152;
B.A.Evans,unpublisheddata).Thismaybedue to itsgenetic location
within the capsule locus in A. baumannii (153), a region of the
genome that is likely to be under selection, which may result in
deletions and recombination. This is supported by evidence that
the gpi locus as well as the gyrB locus (another gene used in the
Oxford scheme), which is located next to the capsule locus, have
undergone horizontal gene transfer (154). A recent analysis of the
data available in the databases for both A. baumannii MLST
schemes found that nearly 60% of 496 isolates belong to one of 26
clones (isolates belonging to the same clonal complex and found
in more than one country), 18 of which were found onmore than
one continent (155). The largest of these clones was represented
by clonal complex 92 (CC92) (Oxford scheme)/CC2 (Pasteur
scheme). This corresponded to the previously identified interna-
tional clone II (156). In terms of acquired OXA-type -lactama-
ses, isolates from this group were found to carry blaOXA-23-like,
blaOXA-40-like, and blaOXA-58-like genes. In contrast, the second larg-
est clone, represented by CC109 (Oxford scheme)/CC1 (Pasteur
scheme), corresponding to international clone I (156), was found
to carry only blaOXA-23-like and blaOXA-58-like genes, while isolates
from CC187 (Oxford scheme)/CC3 (Pasteur scheme), corre-
sponding to international clone III (157), were found to encode
only blaOXA-58-like genes. Other identified clones also carried spe-
cific combinations of acquired blaOXA genes, but CC92/CC2 was
the only clone that appeared to harbor all three major enzyme
groups. This may partly explain the success of this widespread
clonal group. The A. baumannii clones identified also largely cor-
respond with blaOXA-51-like gene clustering (158), as might be ex-
pected, as these genes are naturally found on the A. baumannii
chromosome. However, for a few isolates, there was a mismatch
between the clonal complex to which they belonged and the
blaOXA-51-like gene that they carried. This mismatch, combined
with the fact that blaOXA-51-like genes have been identified on plas-
mids and in other bacterial species (88, 159–162), demonstrates
that these genes can be horizontally transferred and, as such, are
not a reliable method for identifying the underlying bacterial ge-
notype. Another typingmethod that delineatedA. baumannii iso-
lates into sequence groups (SGs) also utilizes the blaOXA-51-like
genes, casting doubt on its reliability for determining the under-
lying isolate genotype (163).
Unlike the AcinetobacterOXA-type -lactamases, genes coding
for the OXA-48 enzyme have spread much more rapidly to far
more bacterial species and genera (Table 1). Therefore, for the
blaOXA-48-like enzymes, it seems as if it is the spread of plasmids
rather than the spread of clonal lineages that is responsible for the
spread of the gene (115, 116). However, the spread of a clone
carrying the blaOXA-48 gene has been identified (164), and it re-
mains to be seenwhethermore such clones will emerge in the near
future, particularly if more structures that reduce the mobility of
the gene, such as that surrounding blaOXA-232, are identified (69).
Ultimately, whether the prevalence of certain blaOXA genes is due
to their hitchhiking with a particularly successful clonal lineage or
whether the success of certain clonal lineages is due to the blaOXA
genes that they possess is not clear.
High-Resolution Typing
One of the most common methods used for fine-scale typing of
bacterial isolates is pulsed-field gel electrophoresis (PFGE). Un-
like MLST, PFGE can identify small differences between isolates
within a clonal outbreak, and as such, it is very useful for local
epidemiological purposes. While PFGE data are often consistent
with MLST data (154), it is not unusual for isolates to have the
sameMLST sequence type but to produce different PFGEpatterns
(152, 165, 166). Another commonly used method is repetitive
sequence-based PCR (rep-PCR) using theDiversiLab system (52),
and the discriminative power of this system is similar to that of
PFGE. The use of these techniques and comparing them with
blaOXA gene content illustrated the degree of mobility that the
blaOXA genes have, where isolates with the same PFGE or rep-PCR
profile vary in their blaOXA gene content (137, 138, 167) or isolates
with different profiles can have the same blaOXA gene content
(152, 167, 168). The use of such techniques with high discrimina-
tory power is useful in outbreak situations, where, when used in
conjunctionwith blaOXA gene screening, they can be used to detect
small changes in local epidemiology, such as the acquisition of a
resistance gene or conversion between one allele of a resistance
gene and another (55, 169).
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FUTURE CONCERNS
Until the discovery of theOXA-23-lactamase, theOXA enzymes
were a relatively minor group of plasmid-encoded -lactamases,
which were active predominantly against the penicillins. The in-
troduction of the carbapenems and the rise of Acinetobacter bau-
mannii has, for theOXA enzymes, opened “Pandora’s box.” There
has been an explosion of new OXA enzymes, many closely related
to each other. For the first time, the chromosomal origins of the
OXA enzymes in both A. baumannii and other Acinetobacter spe-
cies became evident. The migration of these genes onto trans-
posons has allowed them to become the predominantmechanism
of resistance to carbapenems in A. baumannii and a major con-
tributor of resistance in the Enterobacteriaceae. This, of course,
was unpredictable and could not be expected. Now that we are
aware of the diversity and potential of these enzymes, we must try
and determine some strategies to control them, particularly in the
absence of sufficient novel anti-Gram-negative antibiotics. The
	N/	S ratio for each group of OXA enzymes indicates positive
selection and signifies that these enzymes are likely currently still
evolving. This presumably is a result of our use of carbapenems.
We have virtually no understanding of how individual carbapen-
ems have influenced the evolution of individual OXA enzyme
groups, and this is a massive gap in our knowledge, as it would
enable us to alter therapy in an attempt to curb the emergence of
new variants.We do, however, have evidence to suggest that some
drugs that are not supposed to select these enzymes inAcinetobac-
ter baumannii, such as ertapenem, can do so in laboratory exper-
iments and possibly may do so in the clinic (170, 171). Carbapen-
ems that do not kill A. baumannii, whether or not they contain an
active OXA carbapenemase, could provide very powerful selective
environments for the spread and evolution of these genes. Not all
carbapenems are the same, and until we know the impact of indi-
vidual carbapenems on the population, it will be impossible to
stem the evolution of these genes.
So what of the future? The ability of the OXA -lactamases to
confer carbapenem resistance has already had a huge impact on
the ability to treatGram-negative infections. The current situation
suggests that the problem caused by OXA carbapenemases is only
set to increase. It is unlikely that the introduction of new carbap-
enems alone, especially in the absence of data on their impact on
current enzymes, will be able to curb this tide. It is possible that an
OXA -lactamase inhibitor administered with new or even cur-
rent carbapenems could overcome strains with these resistance
genes. However, the huge diversity of blaOXA genes that have al-
ready evolved would suggest that some blaOXA genes may already
be resistant to new inhibitors or may rapidly evolve to be so.
In A. baumannii, the diversity of genes is so great that it is
unlikely that the OXA carbapenemases will ever be controlled, as
the situation with these genes is now very similar to that of the
ESBLs in the Enterobacteriaceae. However, infections caused by
Acinetobacter baumannii are generally limited to severely ill, im-
munocompromised, nosocomial patients. The emergence ofOXA
carbapenemases in the Enterobacteriaceae, particularly Klebsiella
spp., is ofmajor significance because these bacteria are true patho-
gens that are able to infect immunocompetent individuals. So far,
a relatively small number of OXA carbapenemases have emerged
in the Enterobacteriaceae, and their numbers should, and perhaps
could, be reduced or eradicated. This would prolong the active life
of the carbapenems, but very carefulmanagement of carbapenems
would be needed to achieve this. Failure runs the risk that the
diversity of the current OXA carbapenemases will increase so that
no new drugs directed toward OXA -lactamases would be effec-
tive. As carbapenems are often considered the last resort for treat-
ment that does not involve the much more toxic antibiotic colis-
tin, preservation of carbapenem efficacy is essential for continued
clinical success against severe Gram-negative infections.
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